Jiangsu Recbio Technology Co., Ltd (HKG: 2179), a leading Chinese biotechnology company, has announced a strategic licensing and partnership agreement with Saudi Arabian pharmaceutical firm SPIMACO. The agreement pertains to Recbio’s recombinant 9-valent human papillomavirus (HPV) vaccine, REC603. Under the terms of the deal, SPIMACO will secure exclusive rights to develop, regulate, and commercialize the vaccine in Saudi Arabia and across 14 additional countries in the Middle East and North Africa.
REC603, designed for individuals aged 9 to 45, has demonstrated favorable safety and immunogenicity profiles in prior studies and is currently in Phase III clinical trials in China. Recbio’s HPV vaccine production facility, which meets World Health Organization Prequalification (WHO PQ) standards, is capable of producing 20 million doses of the recombinant 9-valent HPV vaccine annually.- Flcube.com
